GlassScriptPhysician profile
Jalyn D Wall
NPI 1073579454
$7,725.95
in general payments reported to CMS, 2019-2025
35 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,168 · 2022: $1,378 · 2023: $2,318 · 2024: $1,346 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,047 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,047.34 |
| Education | $132.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,359.97 | 2021-2025 | |
| Lilly USA, LLC | $822.65 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Exeltis, USA INC. | $700.48 | 2022-2023 | Slynd |
| Abbott Laboratories | $635.78 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $617.50 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $558.88 | 2022 | |
| Novo Nordisk INC | $428.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $383.27 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $356.73 | 2022-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $294.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.50 | 2021-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $225.82 | 2022-2025 | Airsupra, Farxiga |
| Amgen INC. | $208.55 | 2021-2024 | Repatha, Prolia, Evenity |
| Lundbeck LLC | $163.50 | 2024-2025 | Vyepti, Rexulti |
| Axsome Therapeutics, INC. | $114.46 | 2025 | Auvelity, Symbravo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $89.87 | 2022-2024 | Nexplanon |
| Boston Scientific Corporation | $67.65 | 2022-2025 | Watchman Flx |
| Arbor Pharmaceuticals, INC. | $50.54 | 2021 | |
| Inspire Medical Systems, INC. | $47.63 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $44.71 | 2024-2025 | Rexulti |
| Dexcom, INC. | $36.94 | 2023-2024 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $27.31 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.17 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.28 | 2021 | |
| Corcept Therapeutics | $20.75 | 2025 | Korlym |
| Daiichi Sankyo INC. | $19.57 | 2022 | |
| Amarin Pharma, INC. | $19.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2025 | |
| Medtronic, INC. | $18.42 | 2025 | Abre |
| Novartis Pharmaceuticals Corporation | $18.19 | 2021 | |
| Allergan, INC. | $17.63 | 2021 | |
| Exact Sciences Corporation | $17.18 | 2023 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $16.45 | 2023 | |
| Seqirus USA INC | $15.52 | 2025 | Fluad, Flucelvax |
| Idorsia Pharmaceuticals US INC | $14.69 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jalyn Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.